Exploring Kinase Inhibitors: A CDMO Perspective
The whitepaper highlights how protein kinases, which regulate various cellular functions and include about 560 enzymes in the human genome, are linked to cancers and other disorders. Since 2001, over 75 small molecule kinase inhibitors (SMKIs) have been approved by the FDA, primarily for oncology, and new areas are emerging. SMKIs are classified into seven classes based on their binding mode, target, and enzyme state.
SMKI synthesis is a complex process involving diverse chemistry, often utilizing metal-catalyzed cross-coupling. Large-scale GMP manufacturing necessitates control over catalyst deactivation, impurity formation, and residual metals. The recycling of precious metals is crucial for cost and sustainability. In this intricate landscape, manufacturers require versatile technology and robust safety measures, a need that Axplora is adept at fulfilling for potent compounds.
Access gated content
Fill the form below to access this resource.
Related resources
Whitepaper
Dare to use preparative chromatography at industrial scale for your API
Maximise purity, efficiency, and sustainability. Is purification stalling your API journey to market?You’re not alone! Every molecule is a new frontier—with its own complex terrain. But here’s the bold truth: the future belongs to those who dare to imagine better solutions. Preparative chromatography as a powerful purification technology can unlock major benefits for your complex […]
We enable our partners to fully realize their ambitions.
Driven by the curiosity, skills and dedication of over 2,000 employees on three continents, Axplora delivers sustainable, technologically advanced API solutions to improve lives worldwide.